A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. is a phase 2, interventional study registered as NCT05024097 by Weill Medical College of Cornell University, with a registry enrolment figure of 43 participants, started 2022-03-31 and due to reach its primary completion in 2026-12. Interventions recorded: Etrumadenant (AB928); Radiation therapy; FOLFOX regimen; Zimberelimab (AB122). Conditions listed: Rectal Cancer. Primary outcome: Number of treated patients who achieve complete pathologic response. Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of adenocarcinoma of the rectum". Sites: United States. No results are recorded here; the registry entry is the source.